ClinicalTrials.gg
CompletedNCT03475862Updated Mar 23, 2018

Nasal Human Abuse Potential of PTI-821

A Phase 1 interventional study of PTI-821 capsule Manipulated and PTI-821 Non-manipulated in Opioid Abuse Nondependent, sponsored by Pain Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-23.

Sponsored by Pain Therapeutics · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2017, 9 years 3 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled May 2017, registered Mar 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Read the detailed description

The nasal human abuse liability of PTI-821 will be compared to oxycodone IR using pharmacokinetic and pharmacodynamic assessments. A comparison to OxyContin will be dose using pharmacokinetic assessments.

02

Conditions studied

  • Opioid Abuse Nondependent
03

In context

Lead sponsor

Pain Therapeutics is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria::

  • Healthy male and/or female subjects between the ages of 18 and 55 years,
  • Subject is a recreational opioid user who is NOT dependent on opioids
  • (BMI) of 17.5 to 30.5 kg/m2; and body weight > 50 kg (110lbs).
  • Evidence of a personally signed and dated document
  • Subjects must be willing and able to comply with study procedures.
  • Females who are physically incapable of childbearing, or practicing an acceptable method of . Acceptable methods of birth control include surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or diaphragm with a spermicidal agent or intrauterine device).

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine).
  • Has participated in, is currently participating in, or is seeking treatment for substance- and/or alcohol-related disorders (excluding nicotine and caffeine).
  • Has a positive urine drug screen (UDS) excluding tetrahydrocannabinol (THC) at Screening and the admission for Qualification Phase.
  • Has a positive alcohol breath test at Screening or upon admission to the study center for the Qualification Phase.
  • Has any history of a condition in which an opioid is
  • History of sleep apnea in the past 5 years that has not been resolved.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject unsuitable for entry into this study.
  • Positive test for , , or at Screening.
  • Allergy or history of to naloxone hydrochloride (HCl), oxycodone HCl, other opioids, and/or lactose.
  • Any condition possibly affecting drug absorption.
  • Physical (eg, constricted or collapsed veins) or mental obstruction (ie, phobia) that would prevent serial blood sample collection.
  • Clinically significant illness in the judgment of the investigator within 30 days before Screening.
  • Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first treatment during the Qualification Period (Visit 2), if longer than 30 days.
  • Screening BP > 140 mm Hg (systolic) or > 90 mm Hg (diastolic) following at least 5 minutes of rest. If BP is > 140 mm Hg (systolic) or > 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
  • Pregnant females; breastfeeding females; males and females of who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 28 days after the last dose of study medication. Urine pregnancy tests must be collected and confirmed negative prior to dosing upon admission.
  • Is currently taking a drug for a medical condition or a nutraceutical that poses a safety risk when administered with an opioid, cannot be safely withdrawn at Screening for the duration of the study, and/or will adversely affect the PD and safety assessments required by the study. Examples include antihypertensive agents, drugs for seizures, and diabetes medications. Hormonal contraceptives (oral, injected, intrauterine, transdermal or implanted) are allowed in this study provided the subject remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the investigator. As an exception, acetaminophen may be used at doses of 1 g/day.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 30 days prior to dosing.
  • Unwilling or unable to comply with the procedures described in this protocol.
  • Unwilling to be searched (including personal effects) for illicit substances before admission to the study center.
  • Subject is a heavy smoker (> 20 cigarettes per day on average in the past 30 days prior to Screening), chews tobacco, uses nicotine-containing products (including nicotine transdermal patches), and/or is unable to abstain from smoking for at least 10 hours during any day.
  • Current pending legal charges or currently on probation.
  • Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are PTI employees directly involved in the conduct of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    PTI-821 Manipulated

    oxycodone 40 mg capsule

    Drug: PTI-821 capsule Manipulated

  • Active comparator
    Oxycodone

    Oxycodone 40 mg IR tablet crushed

    Drug: Oxycodone

  • Active comparator
    OxyContin

    Oxycodone ER 40 mg tablet crushed

    Drug: OxyContin

  • Placebo comparator
    Placebo

    Matching placebos for experimental and active comparator arms

    Other: Placebo

  • Experimental
    PTI-821 Non-manipulated

    Oxycodone 40 mg non-manipulated

    Drug: PTI-821 Non-manipulated

Interventions

  • PTI-821 (oxycodone) 40 mg extended release capsule

  • PTI-821 (oxycodone) 40 mg capsule extended release capsule

  • Crushed OxyContin (oxycodone) extended-release 40 mg tablet

  • OtherPlacebo

    Matching placebos for PTI-821 and oxycodone IR

  • Crushed oxycodone 40 mg immediate release tablet

06

What researchers measure

Primary outcomes

  1. Drug Liking Emax

    Peak effect for drug liking based on bipolar visual analog scale from 0-100 where 0 is most negative response, 50 is neutral, and 100 is most positive response.

    Time frame: Intervals from 0.5 hours to 12 hours post dose

Secondary outcomes

  1. Take Drug Again

    Desire to take drug again if offered based on bipolar visual analog scale from 0-100 where o is most negative response, 50 is neutral, and 100 is the most positive response.

    Time frame: 12 and 25 hours

  2. Drug effects questionnaire

    Assesses various drug effects such as good drug effects, bad drug effects, high and nausea/dizziness

    Time frame: Intervals from 0.5 hours to 12 hours post dose

  3. Peak Plasma Concentration (Cmax)

    Maximum plasma concentration

    Time frame: Intervals from 15 minutes to 24 hours post-dose

  4. Area under the plasma concentration versus time curve

    Amount of drug absorbed at various timepoints

    Time frame: Intervals from 15 minutes to 24 hours post-dose

  5. Time to maximum plasma concentration (Tmax)

    The time intervals from the first dose to the peak plasma concentration

    Time frame: Intervals from 15 minutes to 24 hours post-dose

07

Study locations

1 site
  • PRA-EDS
    Salt Lake City, Utah 84106, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Jul 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 23, 2018
StartActual
May 15, 2017
Primary completionActual
Jul 31, 2017
CompletionActual
Dec 15, 2017
Last update
Mar 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03475862
Lead sponsor
Pain Therapeutics
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Mar 23, 2018
Start date
May 15, 2017
Primary completion
Jul 31, 2017
Completion
Dec 15, 2017
Last update
Mar 23, 2018

Study contacts

Lynn Webster, MD
principal investigator · PRA Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion